Arima Genomics Completes Early Access Program and Launches the Arima-HiC Platform
Arima Genomics, Inc., a biotechnology company empowering researchers to apply long-range genetic sequence and structure information toward the understanding of health, disease and species evolution, announced today the full commercial launch of its Arima-HiC technology. The Arima-HiC sample preparation kit is a simple and rapid 6-hour protocol that enables detection of long-range chromatin interactions that can be used across multiple applications. The public launch brings to a close a successful Early Access Program that yielded further proof of product performance and valuable feedback from early access customers.
The limited scale of operation of the Early Access Program allowed the company to work closely with customers, leading to an enhanced Arima-HiC offering. “We have been very happy with the Arima-HiC kit,” said Eileen Furlong PhD, Head of the Genome Biology Unit at EMBL. “The Arima-HiC protocol is days quicker than our previous lab's protocol. All together, better quality data for less effort.” In response to customer needs for low sample input studies, the Arima-HiC kit now enables researchers to generate high-quality Hi-C libraries from less than 100K cells, depending on the application. “We are pleased with the ease of the Arima-HiC workflow and the improved data quality for topological domain and chromatin looping analysis,” said Hiruy Meharena PhD, Postdoctoral Fellow at Massachusetts Institute of Technology . “The expanded support for low input is a significant feature as it allows researchers to perform Hi-C across precious samples such as rare cell populations or clinical samples that were previously precluded from Hi-C analysis.”
To facilitate data analysis, the company collaborated with academic partners to optimize established open-source tools, including HiCUP and SALSA for Arima-HiC data. These tools leverage unique aspects of Arima-HiC data, such as greater coverage uniformity and higher long-range signal-to-noise ratio, for improved chromatin conformation and genome assembly analysis. Such engagement with the open source community will continue to be a key focus for the company as part of its sustained efforts to streamline and expedite the sample-to-results workflow. The company is also continuing to work with key academic collaborators on targeted Hi-C approaches along with developing workflows for new genomic applications with industry partner Agilent Technologies.
Feedback and data generated by early access customers also played an important role in further validating the Arima-HiC technology. Recently, the first dataset from Phase I of the Vertebrate Genome Project that leveraged Arima-HiC technology was released. "Arima Genomics is an integral technology partner of the G10K consortium and Phase I of the VGP project,” Gene Myers PhD, G10K Council Member and Director at Max-Planck Institute of Molecular Cell Biology and Genetics, Dresden. “Arima was selected for Phase I based on the quality of their data, proven by their ability to generate reproducible and high-quality data despite variability in input sample quality and quantity. The long-range genomic interactions from Arima-HiC data is an essential component of our current strategy for the generation of chromosome-spanning reference assemblies.”
In addition to high-quality genome assemblies, other labs demonstrated the ability to detect chromatin loops and topologically associated domains (TADs) with high confidence at significantly reduced depth of sequencing compared to other methods. “The ability of Arima-HiC kits to deliver greater insight with less sequencing cost will be critical in enabling more researchers to leverage Hi-C technology for understanding gene regulation within the three-dimensional context of the genome,” said Changhoon Kim PhD, Chief Technology Officer at Macrogen, Inc.
As part of the company’s transition out of early access phase, it has scaled its operations to make the Arima-HiC technology easily accessible to researchers. In addition to expanding its sales team, it has streamlined its order-to-ship process, and enhanced its customer service and support experience. “The commercial launch of the Arima-HiC kit marks a significant milestone in the company’s mission to accelerate the understanding of genome sequence and structure,” said Siddarth Selvaraj, Arima Genomics founder and CEO. “Our goal in this next phase is to enable researchers to gain more insight from the genome by making Hi-C technology as accessible, affordable, and easy-to-use as possible.”
About Arima Genomics
Arima Genomics, Inc. is a biotechnology company that aims to accelerate the understanding of genome sequence and structure and their role in health, disease, and species evolution. For additional information, please visit: www.arimagenomics.com.
Arima Genomics, Inc.
Siddarth Selvaraj, 1-505-948-3116
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Avioq Announces CE Mark and European Launch of VioOne HIV Profile Supplemental Assay24.6.2019 18:11:00 EEST | Tiedote
Avioq, Inc. has received CE Marking (Conformité Européenne) and has begun marketing their VioOne™ HIV Profile™ Supplemental Assay in the European Union and other CE Mark countries. The product has also been submitted for FDA approval. “We are pleased to provide the CE Mark HIV Profile™ assay to countries outside the U.S.,” said Chamroen Chetty, CEO of Avioq. Dr. Chetty continues, “We are also looking for distribution partners to expand the global availability.” The HIV Profile™ is an enzyme-linked immunosorbent assay (ELISA) for confirmation and differentiation of individual antibodies directed to various gene products of HIV-1 (Group M & Group O) and HIV-2 in human serum or plasma that were repeatedly reactive in diagnostic screening procedures. Results can also be used to distinguish recent from longstanding HIV-1 infection for HIV-1 incidence estimation. About Confirmatory Testing In 2014, the CDC released a new algorithm for HIV testing. The second step of the algorithm includes a
Global Launch of S BLOCK, Kicked Off in Singapore on June 22nd24.6.2019 15:29:00 EEST | Tiedote
The globally renowned 2019 WBF Singapore Technology Conference was held in Marina Bay Sands Hotel on June 22nd, 2019. S BLOCK, the conference co-host, unveiled itself and announce its mission to “Unleash your digital assets” for the first time. The conference brought together numerous industry elites and blockchain enthusiasts from all around the world, including more than 500 industry veterans from over 30 countries, such as Switzerland, Germany, France, Russia, Japan, Korea, Brazil, Australia, Argentina and Canada. Insiders shared profound global industry insights. This conference draws great attention from across the global blockchain industry. S BLOCK Kicked Off in Singapore In the morning of June 22nd, Ivan - President of S BLOCK Global Foundation, was invited to deliver a keynote speech, “Next Generation Digital Currency Wallet”. At this conference, S BLOCK was officially launched in more than 30 countries around the world, and opened up the way to a global future without borders
SpeeDx announce a collaborative agreement with GSK to supply tests and technology24.6.2019 15:00:00 EEST | Tiedote
SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, has signed a collaborative agreement with GSK, to provide a combination of existing tests and custom test development to support certain GSK antibiotic clinical trials and new product development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190624005302/en/ “SpeeDx has a demonstrated commitment to improve patient care, and our tests currently used in clinical practice are supporting Resistance Guided Therapy, positively impacting cure rates and helping to minimise the spread of antimicrobial resistant infections.” Colin Denver, SpeeDx CEO. (Photo: Business Wire) “We welcome this extension of the utility and application of our tests and technology,” said Colin Denver, SpeeDx CEO. “SpeeDx has a demonstrated commitment to improve patient care, and our tests currently used in clinical practice are supporting Resistance Guided Therapy, positively impac
Nexon Computer Museum to Hold the Fourth VR Content Contest24.6.2019 13:13:00 EEST | Tiedote
Nexon Computer Museum (NCM) of NXC is holding the fourth virtual reality content contest, ‘2019 NCM OPEN CALL X REALITY’. NXC is a holding company of Nexon (TOKYO: 3659). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190624005284/en/ Nexon Computer Museum (NCM) of NXC is holding the fourth virtual reality content contest 2019 NCM OPEN CALL X REALITY with total prize money of KRW 13 million. Application received from July 1st to August 31st, winners announced on October 25th. (Graphic: Business Wire) NCM OPEN CALL is an exhibit to discover and support virtual reality content creators. This year’s keyword ‘X REALITY’ encompasses all kinds of virtualization including VR, AR, MR, and more. It also implies eXtended Reality, which broadens the perspectives of reality, and Cross Reality, which overlaps the real and virtual world. The unpredictable X signifies NCM OPEN CALL’s pursuit towards embracing various kinds of innovative an
REPLY: New Tool “China Beats” Provides Deep Insights Into the Chinese Market24.6.2019 12:15:00 EEST | Tiedote
TD Reply, the company specializing in marketing and innovation consulting within the Reply Group, developed China Beats, a business intelligence solution that enables companies to gain an in-depth understanding of the Chinese market and its players. This is ensured by AI-supported social listening with connection to all major Chinese e-commerce, social media and search platforms such as Alibaba, Baidu, WeChat and Weibo. The prosperity of the Chinese population is growing at a rapid pace. According to analysts estimates, around 550 million Chinese will belong to the middle class by 2022. As a result, the Chinese market is also becoming increasingly important for international companies. Entering the market, however, is challenging, especially in terms of reliable identification of target groups, analysis of their consumer behavior and preferences. Digital data can provide a remedy, because the majority of Chinese consumers are netizens who shop on digital platforms, exchange their opini
MYbank Works With Financial Institution Partners to Serve Over 15 Million SMEs24.6.2019 08:42:00 EEST | Tiedote
MYbank, a leading online private commercial bank in China with a focus on SME financing, today announced that the bank’s Star Plan has enabled MYbank, with its financial institution partners, to serve over 15 million small and micro enterprises (SMEs). SMEs are key drivers of economic growth and this partnership is now serving more SMEs than any other in the world. The announcement comes on the day that MYbank celebrates its 4th Anniversary. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190623005055/en/ MYbank’s 310 lending model enables inclusive finance for SMEs in China (Photo: Business Wire) MYbank’s Star Plan was announced on June 21, 2018 with the aim of using technology to enable 1,000 financial institution partners to provide more cost-effective financing services to 30 million SMEs in China within a three-year period. A little over a year later and the Star Plan is showing significant progress. As of June 2019, lev
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme